Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients-Reference-Cited by-同舟云学术

Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients

Published:2013-04 Issue:4 Volume:8 Page:461-468
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Russell Prudence A.,Barnett Stephen A.,Walkiewicz Marzena,Wainer Zoe,Conron Matthew,Wright Gavin M.,Gooi Julian,Knight Simon,Wynne Rochelle,Liew Danny,John Thomas

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Pathology and genetics: tumours of the lung, pleura, thymus and heart;Travis,2004

3. Small adenocarcinoma of the lung. Histologic characteristics and prognosis;Noguchi;Cancer,1995

4. Histologic features are important prognostic indicators in early stages lung adenocarcinomas;Yim;Mod Pathol,2007

5. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma;Borczuk;Am J Surg Pathol,2009

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting invasion in early-stage ground-glass opacity pulmonary adenocarcinoma: a radiomics-based machine learning approach;BMC Medical Imaging;2024-09-13

2. Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management;Lung Cancer;2024-01

3. Molecular Pathogenesis of Lung Cancer: Evolving Landscapes Based on Past Experience;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

4. Computed Tomography Radiomics for Preoperative Prediction of Spread Through Air Spaces in the Early Stage of Surgically Resected Lung Adenocarcinomas;Yonsei Medical Journal;2024

5. Histology and molecular testing;Lung Cancer;2024